Abstract

Humoral rejection processes may lead to allograft injury and subsequent dysfunction. Today, only one B-cell specific agent is in clinical use and the effects of standard and new immunosuppressant substances on B-cell activation and function are not fully clarified. The impact of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function was assessed by analysing proliferation, apoptosis, CD80 expression and immunoglobulin production in primary stimulated B-cells. In addition, B-cell co-cultures with pre-activated T-cells were performed to evaluate the effect of the different immunosuppressive agents on T-cell dependent immunoglobulin production. Sotrastaurin did not inhibit B-cell proliferation, CD80 expression and IgG production and had only minor effects on IgM levels at the highest concentration administered. In contrast, mycophenolic acid and everolimus had strong effects on all B-cell functions in a dose dependent manner. All immunosuppressive agents caused decreased immunoglobulin levels in T-cell dependent B-cell cultures. The data provided here suggest mycophenolic acid and everolimus but not sotrastaurin are potent inhibitors of human B-lymphocyte function and activation.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call